Neuraxpharm and Pharmathen have signed a co-development agreement to develop long-acting injectable (LAI) therapies for the psychiatry sector.
Neuraxpharm, a European speciality pharmaceutical company, specialises in central nervous system (CNS) disorders.
Pharmathen is a pharmaceutical company in Greece focused on LAI therapies.
The partnership aims to advance psychiatric treatment using Pharmathen’s long-acting therapeutic technologies (LATT) programme.
Under the agreement, Neuraxpharm gains rights to commercialise the therapies in Europe and regions where it has a direct presence.
Pharmathen will hold rights for North America and all other countries not covered by the European drug maker.
Neuraxpharm CEO Jörg-Thomas Dierks said: “Today’s announcement reflects our ongoing commitment to bringing innovative solutions to CNS patients in Europe and beyond.
“These are well-established therapies, but we are bringing them to the market in a new format, which will offer patients greater flexibility and control in how they manage what are often challenging conditions.”
Pharmathen’s LATT programme leverages proprietary technologies to transform traditional short-acting dosage forms, like tablets and injectables, into long-acting injectable therapies.
These therapies address the unmet needs of prescribers and patients, offering better long-term symptom control, improved patient compliance, and enhanced convenience during patient treatment.
With a track record in developing and launching LAI products worldwide, Pharmathen will serve as the technological, manufacturing, and supply partner.
Neuraxpharm, known for its commercialisation expertise in CNS products across Europe, will handle product registration and marketing in Europe and other markets where it has a direct presence.
The European pharmaceutical company operates in over 20 European countries and has affiliates in Latin America, the Middle East, and a global distribution network.
Pharmathen Group CEO Dimitris Kadis said: “At Pharmathen, our mission is to improve patients’ lives through innovation and quality.
“This collaboration is an important step toward achieving that goal by enhancing access, convenience, and choice for our patients as we bring our long-acting therapeutic technology products to more prescribers and CNS patients worldwide.”
In August last year, Neuraxpharm signed an ex-US commercialisation agreement with TG Therapeutics for Briumvi (ublituximab), an anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis.
